Alan joined Matrix Capital Management as a Managing Director in 2021. Previously he was a Partner at Sofinnova. He focuses on clinical-stage product companies, particularly in oncology, rare diseases and other specialty therapeutic areas. In addition to serving on the InCarda Therapeutics Inc. board, he serves as Executive Chairman of Principia Biopharma and VelosBio, and Board member of Xylocor Therapeutics and Human Longevity, Inc.
Before joining Sofinnova, Alan held executive management and board of director positions at numerous biotechnology companies. Most recently, he was Executive Vice President at Celgene Corporation, and prior to that held positions of President for Celgene’s Europe, Mid-East, and Africa regions as well as Senior Vice President of Global Medical Affairs. Previously, Alan was the Chief Executive Officer at Gloucester Pharmaceuticals, Inc. until its acquisition by Celgene in 2010. Before becoming CEO at Gloucester Pharmaceuticals he was President, Oncology for Geron Corporation and was Chief Medical Office of Threshold Pharmaceuticals. Prior to that, Alan held numerous positions of increasing responsibility at Amgen Inc culminating with his role as VP, Medical Affairs Europe.
Alan received an M.D. from Stanford University and an M.P.H. from Harvard University. He completed specialty training in Hematology-Oncology at the Dana Farber Cancer Institute and Brigham and Women’s Hospital. Alan has a B.S. in Molecular Biology from the University of Colorado.